Abstract
Patients with cutaneous chronic GVHD (cGVHD) often undergo a progression to a sclerodermatous phase. This occurs in three pathways following a generalized lichenoid inflammatory state, less commonly out of a morpheic state or as eosinophilic fasciitis. The changes include fibrous remodeling of the dermal collagen, which eventually leads to dense dermal fibrosis and fibrosis within the underlying subcutaneous fat, resulting in contractures and frozen joints. The evolution from an inflammatory to sclerotic phase is a continuum. The pandermal sclerosis may be modified by immunosuppression, and there is variability from different sites. Evaluation of sclerodermatous chronic GVHD requires a full-thickness biopsy. However, because it is difficult to distinguish static from active changes, the diagnosis often relies on clinical evaluation. A framework for evaluating fibrosis after clinical intervention is proposed. Sclerodermatous cGVHD phenotypically resembles progressive systemic sclerosis (PSS). Pathobiological studies of the microvasculature’s role in the genesis of sclerosis indicate normal dermal capillary architecture and endothelial phenotype in cGVHD in contrast to PSS. Studies regarding a reduction of dermal vessels in patients with cGVHD are discordant. The current thinking is that the sclerosis evolves from a combination of cytokines and B-cell hyper-reactivity, leading to prolonged stimulation of fibrosis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Inamoto Y, Storer BE, Petersdorf EW, et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood. 2013;121(25):5098–103.
Signori A, Crocchiolo R, Oneto R, et al. Chronic GVHD is associated with lower relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors. Bone Marrow Transplant. 2012;47(11):1474–8.
Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56.
Bilic E, Delimar V, Desnica L, et al. High prevalence of small- and large-fiber neuropathy in a prospective cohort of patients with moderate to severe chronic GvHD. Bone Marrow Transplant. 2016;51(11):1513–7.
Gathings RM, Reddy R, Santa Cruz D, Brodell RT. Gadolinium-associated plaques: a new, distinctive clinical entity. JAMA Dermatol. 2015;151(3):316–9.
Fleming JN, Nash RA, McLeod DO, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One. 2008;3(1):e1452.
Aschwanden M, Halter JP, Walker UA, et al. Nail fold capillaroscopy differs widely between systemic sclerosis and chronic graft vs host disease of the skin. Rheumatology (Oxford). 2011;50(6):1168–9.
Hofstee HM, de Waal TT, Zweegman S, et al. Nailfold capillary abnormalities in sclerodermatous chronic GVHD. Bone Marrow Transplant. 2013;48(12):1574–7.
Biedermann BC, Sahner S, Gregor M, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet. 2002;359(9323):2078–83.
Fleming JN, Shulman HM, Nash RA, et al. Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. PLoS One. 2009;4(7):e6203.
Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377(26):2565–79.
Alexander KA, Flynn R, Lineburg KE, et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest. 2014;124(10):4266–80.
Yamakawa T, Ohigashi H, Hashimoto D, et al. Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease. Blood. 2018;131(13):1476–85.
Wang KS, Kim HT, Nikiforow S, et al. Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood. 2017;130(26):2889–99.
Inamoto Y, Martin PJ, Flowers ME, et al. Genetic risk factors for sclerotic graft-versus-host disease. Blood. 2016;128(11):1516–24.
Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008;26(4):431–42.
Socie G. Treating chronic GVHD-induced fibrosis? Blood. 2018;131(13):1396–7.
MacDonald KPA, Betts BC, Couriel D. Emerging therapeutics for the control of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2018;24(1):19–26.
Du J, Paz K, Flynn R, et al. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-beta production. Blood. 2017;129(18):2570–80.
Carpenter PA. How I conduct a comprehensive chronic graft-versus-host disease assessment. Blood. 2011;118(10):2679–87.
Verrecchia F, Laboureau J, Verola O, et al. Skin involvement in scleroderma – where histological and clinical scores meet. Rheumatology (Oxford). 2007;46(5):833–41.
Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood. 2007;110(4):1388–96.
Shulman HM, Cardona DM, Greenson JK, Hingorani S, Horn T, Huber E, Kreft A, Longerich T, Morton T, Myerson D, Prieto VG, Rosenberg A, Treister N, Washington K, Ziemer M, Pavletic SZ, Lee SJ, Flowers MED, Schultz KR, Jagasia M, Martin PJ, Vogelsang GB, Kleiner DE. NIH consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 pathology working group report. Biol Blood Marrow Transplant. 2015;21(4):589–603.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Hyun, T.S., Shulman, H.M. (2019). Cutaneous Chronic GVHD: Sclerodermatous and Morpheic Variants. In: Yeung, C., Shulman, H. (eds) Pathology of Graft vs. Host Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-42099-8_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-42099-8_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42098-1
Online ISBN: 978-3-319-42099-8
eBook Packages: MedicineMedicine (R0)